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palliative therapy, simple WBRT or simple chemotherapy, combined 
radiochemotherapy, stereotactic linac-based radiosurgery plus che-
motherapy/ WBRT and neurosurgical resection plus chemotherapy/ 
WBRT. Ninety-two specimens of lung cancer were examined for P53, 
nm23 and VEGF by immunohistochemical staining. Survival analysis 
was compared with Kaplan-Meier method and log-rank test was used 
respectively. Statistical signiﬁcance was deﬁned as P<0.05. 
Results: The univariate analysis showed that performance status, age, 
the number of brain metastases, the absence or presence of extracranial 
metastases and metastatic symptoms had inﬂuences over survival pe-
riod. The multivariate analysis showed that performance status, age and 
the absence or presence of extracranial metastases were related to prog-
nosis. The median survival time of patients receiving palliative therapy, 
simple WBRT or simple chemotherapy, combined radiochemotherapy, 
stereotactic linac-based radiosurgery plus chemotherapy/ WBRT and 
neurosurgical resection plus chemotherapy/ WBRT was 1.7 months, 
3.2 months, 9.0 months, 10.6 months and 17.1 months respectively. 
The median survival time of patients with P53(+)/P53(-), nm23(+)/(-) 
and VEGF(+)/(-)was 11.7/10.6months (P=0.5179), 12.8/9.9 months 
(P=0.1075) and 10.6 /12.0 months (P=0.0231) respectively. 
Conclusions: Performance status, age and the absence or presence of 
extracranial metastases are the independent prognostic factors. The 
patients with PS score 0~1, age< 60 years and the absence of extracra-
nial metastases have longer survival time and they would beneﬁt from 
aggressive treatment modalities. Either combined radiochemotherapy 
or stereotactic linac-based radiosurgery plus chemotherapy/ WBRT 
is effective. There is a longer survival tendency in patients receiving 
stereotactic linac-based radiosurgery plus chemotherapy/ WBRT. The 
expression of VEGF is related to the survival of the patients while 
the expression of P53 and nm23 is unrelated to the survival time. The 
patients with VEGF positive expression have shorter survival time.
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Purpose: The purpose of this study was to evaluate the feasibility of 
sleeve lobectomy after induction chemoradiotherapy.
Methods: We reviewed seven patients who underwent sleeve lobec-
tomy after inductin chemoradiotherapy(Group A) for locally advanced 
non-small cell lung cancer, and 19 patients who underwent sleeve 
lobectomy without induction therapy(Group B). 
Results: The complication of group A was in 3 (33%) of 7 cases, 1 
necrosis of apex of lower lobe, 1 atelectasis and 1 arrhythmia. Of 
group B was in 9(47%) of 19 cases, 2 failure of anastomosis, 3 air 
leakage>7day, 3 wound infection, 2 arrhythmia, 2 recurrent nerve palsy, 
and 1 pneumonia. The recurrence of group A was in 2(29%) of 7 cases. 
One case was brain on the 220th and pulmonary on the 430th. Another 
one case was kidney on the 365th and duodenum on the 700th. The 
recurrence of group B was in 3(16%) of 19 cases, which were observed 
in 1 pulmonary, 1 skin, and 1 plural, respectively.
Conclusions: The complication of bronchial anastomosis and local 
recurrence was not permitted in group A. Although it is a small number 
of study, sleeve lobectomy with induction chemoradiotherapy is con-
sidered to be feasible technique from safety and oncologically.
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Background: Conventional treatment for non-small cell lung cancer 
(NSCLC) brain metastases (BM) is whole-brain radiotherapy (WBRT). 
The efﬁcacy is limited. It might be increased by a potent radiosen-
sitiser such as gemcitabine, which is believed to cross the disrupted 
blood–brain barrier. Primary objective of this study was to determine 
the maximum tolerated dose (MTD) of weekly gemcitabine given 
concurrently with WBRT. 
Methods: Patients with BM from NSCLC were included. The dose of 
WBRT was 3750 cGy (total 15 times, 3 weeks). Gemcitabine was given 
concurrent with WBRT on days 1 and 8 and 15. Starting dose was 400 
mg/m2, escalated by 100 mg/m2 increments. At least three patients were 
included per level. Dose limiting toxicity (DLT) was deﬁned as grade 
4 hematological or grade 2 neurological toxicity. When two or more 
patients experience DLT, the MTD was reached. 
Results: A total of 16 patients were included; 69% had a PS 1. A total 
of 69% had concurrent active extra cranial diseases. All had more than 
3 BM. Up to 600 mg/m2 (level 3) no neurology toxicity was observed. 
At 600 mg/m2, two out of 6 patients developed grade 4 thrombocyto-
penia. One of the two patients’ thrombocytopenia was confused with 
disseminated intravascular coagulation (DIC). At 700 mg/m2, two out 
of 4 patients developed neurotoxicities. One developed grade 3 seizure 
and confusion. Another patient developed suspected grade 2 muscle 
weakness(neuropathy motor). 
Conclusions: The MTD was reached at dose 700 mg/m2. The dose of 
600 mg/m2 would be considered for further study. 
This study was supported by the China Society Clinical of Oncology 
foundation (No.Y-2005--0010) 
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Background: In patients with advanced (stage IIIb/IV) NSCLC, the 
addition of cetuximab to chemotherapy has demonstrated increased 
activity compared with chemotherapy alone. Furthermore, the addition 
of cetuximab to RT in patients with locally advanced squamous cell 
head & neck carcinoma signiﬁcantly prolongs the duration of locore-
gional control and median overall survival compared to radiotherapy 
alone. Therefore, the SCRATCH study was designed to assess the 
safety of synchronous cetuximab with radical RT in patients with Stage 
III NSCLC. The safety results of cohort 1 from this phase I study are 
presented below.
Methods: Twelve patients with inoperable stage III NSCLC were en-
rolled into cohort I. Inclusion criteria were performance status 0-1, ad-
equate organ function, and disease encompassable within a radical RT 
volume. Exclusion criteria were previous malignancy, thoracic RT or 
treatment with EGFR (epidermal growth factor receptor) targeted thera-
py. Patients received platinum-based induction chemotherapy, followed 
by weekly intravenous cetuximab (initial dose 400mg/m2; maintenance 
dose 250mg/m2) and concomitant RT (64Gy/32fractions/45days). The 
primary end-point was toxicity. NCI Common Toxicity Criteria (CTC) 
V3.0 assessments were performed weekly during radiotherapy, and at 
regular follow-up visits.
Results: Complete data from the ﬁrst ten patients is available. The ﬁnal 
2 patients were still receiving concomitant cetuximab and RT at the 
time of abstract submission, and so only provide acute toxicity data. 
Two patients stopped receiving concomitant cetuximab due to toxicity. 
One experienced grade 3 fatigue following the initial dose, and the 
other declined further treatment after developing grade 2 skin toxicity. 
Two patients have died, one from disease progression and one from 
thromboembolic disease. Both deaths occurred between months 2 and 
4 post RT and were not attributed to the cetuximab therapy. Of the 8 
living patients, 4 have survived at least 1 year (measured from the ﬁrst 
day of induction chemotherapy). The maximum NCI CTC v3.0 scores 
are summarised in the table below:
 T O X I C I T Y  
 Lung Lung
Esoph-
agus
Esoph-
agus
Skin Skin
Chest 
pain
Chest 
pain
Sys-
temic
Sys-
temic
Grade RT FU RT FU RT FU RT FU RT FU
Zero 9 5 5 9 2 5 10 8 6 6
1 3 4 7 1 6 5 2 2 5 4
2 - - - - 4 - - - - -
3 - 1 - - - - - - 1 -
NA - 2 - 2 - 2 - 2 - 2
RT = During RT; FU = During Follow-Up Post RT; NA= not yet available
Conclusions: The results suggest that the early and late toxicities of 
synchronous cetuximab and radical RT are acceptable. Complete data 
on all twelve patients will be available by September 2007. SCRATCH 
Study cohorts II-IV follow on and will recruit sequentially. They will 
assess the safety of adding concomitant cisplatin and vinorelbine to ce-
tuximab and radical RT. Early data from cohort II will also be available 
by September 2007.
P2-185 NSCLC: Combined Modality Therapy Posters, Tue, Sept 4 
Age-related acute toxicity in patients with locally advanced non-
small cell lung cancer treated with combined radiochemotherapy. 
Isakovic-Vidovic, Suzana 
Institute for Oncology and Radiology of Serbia, Beograd, Serbia
Aim: The aim of this study was to evaluate age-related acute toxicity 
in patients with locally advanced non-small cell lung cancer (NSCLC), 
treated with the combination of radiotherapy with low doses of carbo-
platin given as radiosensitizer. 
Patients and Methods: The study group consisted of 67 patients. 
They were ﬁrst treated with TD30 Gy in 10 fractions during 2 weeks 
(5 fractions per week) Carboplatin 20 mg/m2 i.v. bolus injection just 
prior to each radiotherapy fraction was administered as radiosensitizer. 
After a 2-week pause, additional radiation of 25 Gy in 10 fractions 
was applied during 2 weeks (5 fractions/week) again with carboplatin 
radiosensitization. The total tumor dose (TTD) was 55 Gy (30+25 Gy) 
in 20 fractions, total duration of the therapy was 6 weeks, and total 
dose of carboplatin was 600 mg. The control group consisted of 70 
patients who were treated with radical radiotherapy with conventional 
fractionation (60 Gy in 30 fractions, 2 Gy per day, 5 fractions per 
week). Both groups were divided in to 3 subgroups related by the age 
of the patients. First subgroup includes patient under the 50 years old, 
seconde subgroup includes patients age between 50-59 years and the 
third subgroup includes patients over 60 years old. 
Results: In study group normal value of haemoglobin was detected 
at the most of patient in all subgroups (85.71% vs. 78.57% vs. 84%). 
Leucopenia was the most frequent in third subgroup (21.43% vs. 
21.43% vs. 36.1%) without statistical signiﬁcance. Thrombocytopenia 
(grade I) in study group was most frequent in patient over 60 year old 
(16%) with statistical signiﬁcance. Acute nausea most grade I in study 
group were the most frequent observed in third subgroup with statisti-
cal signiﬁcance (14.29% vs. 21.43% vs. 48%). Acute oesophagitis 
was uniformly distributed in all subgroups (50% vs. 53.67% vs. 60%) 
mostly grade I-II. Also creatinin clearance grade I was most frequent 
in the subgroup 3 with statistical signiﬁcance (14.29% vs. 21.43% 
vs. 52%). Temperature as acute toxicity was statistically signiﬁcance 
most infrequent in second subgroup, in ﬁrst and third subgroup was 
almost equally distributed mostly grade I-II (35.71% vs. 7.14% vs. 
32%). Cough was the most frequent acute toxicity in all three sub-
groups (64.29% vs. 46.43% vs. 64%), equally distributed in ﬁrst and 
third subgroup. Pneumonitis as acute toxicity was not observed in all 
subgroups. In control group age-related acute toxicity was not detected 
between subgroups with statistical signiﬁcance. Mild acute toxicity 
was especially pronounced in patients over 60 years (third subgroup) 
statistically signiﬁcance more experienced in radiochemotherapy group 
in all parameters. Between second subgroups statistically signiﬁcant 
acute toxicity were observed only with acute oesophagitis creatinin 
clearance and cough, mostly grade I-II in study group. In ﬁrst subgroup 
the youngest patients statistically signiﬁcance were observed in study 
group due the temperature grade I-II and cough grade I-II. 
Conclusion: These results showed that the combined radiochemothera-
py treatment was well tolerated in all age of patients, as well as patients 
over 60 years old, with acceptable rate of acute toxicity. 
